Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healios KK ( (JP:4593) ) has provided an update.
Healios K.K. released its FY2025 financial results materials primarily to disclose information to investors and other stakeholders, emphasizing that the data and analysis are provided for informational purposes only. The company underscores that the materials are not an offer or solicitation to buy or sell securities, and that the contents may change without notice as economic, regulatory and market conditions evolve.
The announcement highlights extensive caution around forward-looking statements, noting that projections and plans are based on current assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially. Healios also stresses that it does not guarantee the accuracy or completeness of the information, is under no obligation to update it, and that third-party data has not been independently verified, while information about regenerative medicine products is not intended as advertising or medical advice.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen358.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
Healios K.K. is a Japan-based biotechnology company focused on regenerative medicine. The company works on the research, development and potential commercialization of regenerative therapies, including cell-based products that target unmet medical needs in areas such as tissue repair and functional recovery.
Average Trading Volume: 4,026,435
Technical Sentiment Signal: Sell
Current Market Cap: Yen42.47B
For detailed information about 4593 stock, go to TipRanks’ Stock Analysis page.